KNSA Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interl…
Industry Peers
Drug Manufacturers - Specialty & Generic| Headline | Source | Time |
|---|---|---|
Older | ||
 Kiniksa Pharmaceuticals International (KNSA) On The ARCALYST Story And Whether Shares Look Fully Valued Kiniksa Pharmaceuticals International (KNSA) has drawn fresh attention after recent share performance data highlighted sharp swings, with the stock down about 4% over the past month but up roughly 34% in the past 3 months. Short term momentum for Kiniksa Pharmaceuticals International has cooled a little, with the share price down over the past month. However, the 90 day share price return of 33.73% and year to date gain of 81.12% point to a strong upswing overall. Compare Kiniksa... | ||
 Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why KNSA is gaining momentum as Arcalyst sales surge and pipeline advances strengthen prospects for continued growth. | ||
 Biopharmaceutical Leader Kiniksa Poised To Hit New Buy Point After Big Revenue Beat Biotech leader Kiniksa stock is poised to hit a fresh buy point after shares soared 25% in response to better-than-expected sales numbers. | ||
 TGTX Stock Outperforms 95% of Stocks. Here's Why. Biotech stock TG Therapeutics is building a cup base after a sell-off in early August. It is testing a key moving average. | ||
 Kiniksa's Sales Are Expected To Decline — Why That's All According To Plan Sales of Kiniksa Pharmaceuticals' biggest product, Arcalyst, are expected to begin declining in 2030. But the company has a plan. | ||
 Three Biotech Stocks Stick Out With Their Stellar Charts These biotech stocks all popped after their recent earnings reports. All three have outperformed 97% of stocks in the last 12 months. | ||
 Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3 Kiniksa Pharmaceuticals International (NASDAQ:KNSA) said its commercialized recurrent pericarditis treatment ARCALYST continues to grow, while the company has begun a pivotal Phase 3 study of follow-on candidate KPL-387. Speaking at a Canaccord Genuity event, Chief Operating Officer Ross Moat said | ||
 KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook KNSA lifted 2026 ARCALYST sales guidance as Q2 revenue surged, while advancing KPL-387 into Phase 3 to support its next growth driver. | ||
 MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth Madrigal beats Q2 estimates as Rezdiffra sales lift revenues 71% year over year, but shares fall as investors weigh slower commercial growth. | ||
 Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain? Kiniksa Pharmaceuticals International, plc (KNSA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. | ||
 Could Kiniksa Pharmaceuticals International (KNSA) Be 16% Overvalued After Raised 2026 Guidance? Kiniksa Pharmaceuticals International (KNSA) just raised its 2026 net product revenue guidance to a range of US$980 million to US$995 million after releasing second quarter results and updating investors on its pipeline. See our latest analysis for Kiniksa Pharmaceuticals International. The raised 2026 guidance and strong second quarter update follow a sharp move in Kiniksa Pharmaceuticals International's stock, with an 8.1x five year total shareholder return and a 92.6% year to date share... | ||
Why Kiniksa Pharmaceuticals (KNSA) Is Up 29.6% After Raising 2026 Revenue Guidance And Advancing Pipeline Kiniksa Pharmaceuticals International, plc recently reported its second-quarter 2026 results, with revenue rising to US$243.6 million and net income to US$25.43 million, and it raised full-year 2026 net product revenue guidance to a range of US$980 million to US$995 million from US$930 million to US$945 million. Beyond the headline growth, the company’s upgraded outlook and progress on its cardiovascular pipeline, including the Phase 3 program for KPL-387 in recurrent pericarditis, highlight... | ||
 Kiniksa Pharmaceuticals, Ltd. Q2 2026 Earnings Call Summary Moby summary of Kiniksa Pharmaceuticals, Ltd.'s Q2 2026 earnings call | ||
 Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Down ALKS posts break-even Q2 earnings and tops revenue estimates as product sales surge, with Lumryz adding momentum. The company maintains its 2026 revenue view. | ||